Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Therapeutic T cell engineering.

Sadelain M, Rivière I, Riddell S.

Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Review.

2.

T cell progenitor therapy-facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction.

Smith MJ, Reichenbach DK, Parker SL, Riddle MJ, Mitchell J, Osum KC, Mohtashami M, Stefanski HE, Fife BT, Bhandoola A, Hogquist KA, Holländer GA, Zúñiga-Pflücker JC, Tolar J, Blazar BR.

JCI Insight. 2017 May 18;2(10). pii: 92056. doi: 10.1172/jci.insight.92056. [Epub ahead of print]

3.

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Rivière I, Sadelain M.

Mol Ther. 2017 May 3;25(5):1117-1124. doi: 10.1016/j.ymthe.2017.03.034. Epub 2017 Apr 26. Review.

PMID:
28456379
4.

Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.

Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, Bonte S, Taghon T, Leclercq G, Kerre T, Debets R, Vermijlen D, Abken H, Vandekerckhove B.

Oncoimmunology. 2017 Jan 19;6(3):e1283460. doi: 10.1080/2162402X.2017.1283460. eCollection 2017.

5.

Acute myeloid leukemia targets for bispecific antibodies.

Hoseini SS, Cheung NK.

Blood Cancer J. 2017 Feb 3;7(2):e522. doi: 10.1038/bcj.2017.2. Review.

6.

Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.

Torikai H, Cooper LJ.

Mol Ther. 2016 Aug;24(7):1178-86. doi: 10.1038/mt.2016.106. Epub 2016 May 16. Review.

7.

Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform.

Hübner J, Hoseini SS, Suerth JD, Hoffmann D, Maluski M, Herbst J, Maul H, Ghosh A, Eiz-Vesper B, Yuan Q, Ott M, Heuser M, Schambach A, Sauer MG.

Mol Ther. 2016 Aug;24(7):1216-26. doi: 10.1038/mt.2016.89. Epub 2016 May 3.

8.

Thymus: the next (re)generation.

Chaudhry MS, Velardi E, Dudakov JA, van den Brink MR.

Immunol Rev. 2016 May;271(1):56-71. doi: 10.1111/imr.12418. Review.

9.

In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination.

Smith MJ, Webber BR, Mohtashami M, Stefanski HE, Zúñiga-Pflücker JC, Blazar BR.

Stem Cells. 2015 Nov;33(11):3174-80. doi: 10.1002/stem.2115. Epub 2015 Aug 11. Review.

10.

Cytokine-induced killer (CIK) cells: from basic research to clinical translation.

Guo Y, Han W.

Chin J Cancer. 2015 Mar 5;34(3):99-107. doi: 10.1186/s40880-015-0002-1. Review.

11.

New cell sources for T cell engineering and adoptive immunotherapy.

Themeli M, Rivière I, Sadelain M.

Cell Stem Cell. 2015 Apr 2;16(4):357-66. doi: 10.1016/j.stem.2015.03.011. Review.

12.

Inducible T-cell receptor expression in precursor T cells for leukemia control.

Hoseini SS, Hapke M, Herbst J, Wedekind D, Baumann R, Heinz N, Schiedlmeier B, Vignali DA, van den Brink MR, Schambach A, Blazar BR, Sauer MG.

Leukemia. 2015 Jul;29(7):1530-42. doi: 10.1038/leu.2015.20. Epub 2015 Feb 5.

13.

CD28z CARs and armored CARs.

Pegram HJ, Park JH, Brentjens RJ.

Cancer J. 2014 Mar-Apr;20(2):127-33. doi: 10.1097/PPO.0000000000000034. Review.

14.

Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

Maus MV, Grupp SA, Porter DL, June CH.

Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27. Review.

15.

Recombinant IL-7/HGFβ hybrid cytokine enhances T cell recovery in mice following allogeneic bone marrow transplantation.

Lai L, Zhang M, Song Y, Rood D.

PLoS One. 2013 Dec 12;8(12):e82998. doi: 10.1371/journal.pone.0082998. eCollection 2013.

16.

Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Ghosh A, Holland AM, van den Brink MR.

Immunol Rev. 2014 Jan;257(1):226-36. doi: 10.1111/imr.12142. Review.

17.

Clinical strategies to enhance thymic recovery after allogeneic hematopoietic stem cell transplantation.

Velardi E, Dudakov JA, van den Brink MR.

Immunol Lett. 2013 Sep-Oct;155(1-2):31-5. doi: 10.1016/j.imlet.2013.09.016. Epub 2013 Oct 8. Review.

18.

Notch signaling in hematopoietic cell transplantation and T cell alloimmunity.

Ebens CL, Maillard I.

Blood Rev. 2013 Nov;27(6):269-77. doi: 10.1016/j.blre.2013.08.001. Epub 2013 Aug 31. Review.

19.

Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.

Ghosh A, Dogan Y, Moroz M, Holland AM, Yim NL, Rao UK, Young LF, Tannenbaum D, Masih D, Velardi E, Tsai JJ, Jenq RR, Penack O, Hanash AM, Smith OM, Piersanti K, Lezcano C, Murphy GF, Liu C, Palomba ML, Sauer MG, Sadelain M, Ponomarev V, van den Brink MR.

J Clin Invest. 2013 Jun;123(6):2654-62. doi: 10.1172/JCI66301. Epub 2013 May 15.

20.

The basic principles of chimeric antigen receptor design.

Sadelain M, Brentjens R, Rivière I.

Cancer Discov. 2013 Apr;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. Epub 2013 Apr 2. Review.

Supplemental Content

Support Center